DGAP-News

MagForce AG Publishes Financial Results for H1/2021 and Operative Highlights

DGAP-News: MagForce AG / Key word(s): Half Year Report MagForce AG Publishes Financial Results for H1/2021 and Operative Highlights 28.10.2021 / 08:30 The issuer is solely responsible for the content of this announcement. MagForce AG Publishes Financial Results for H1/2021 and Operative Highlights

- Europe: Significant upward trend - both in patient numbers and in the number of centers in Europe offering NanoTherm therapy

- USA: Stage 2a of pivotal single-arm study for the focal ablation of intermediate risk prostate cancer successfully completed - Stage 2b with final protocol to start in the short term

Berlin, Germany, and Nevada, USA, October 28, 2021 - MagForce AG (Frankfurt, Scale, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today published its financial results as of and for the first half-year ended June 30, 2021 as well as operative highlights.

Operative Highlights

Europe - Brain Cancer Treatment: Despite of COVID-19 related delays in the installation of additional NanoActivator devices in partner clinics, MagForce has continued discussions and was pleased to announce in September 2021 that a collaboration agreement with Complejo Hospitalario Integral Privado (CHIP), Málaga, was signed - the first clinic in Spain to offer MagForce's NanoTherm therapy for the commercial treatment of glioblastoma patients. The private clinic will be equipped with MagForce's 'plug-and-treat' solution - a mobile container fully operational with a pre-installed NanoActivator device, allowing for a significantly shortened set-up time to start patient treatments. Subject to inspections and permissions by local authorities, commercial treatments are expected to commence in the first half of 2022. To support reimbursement in Spain, an Investigator-Initiated Trial (IIT) with the NanoTherm therapy system is planned at Carlos Haya University Hospital in Málaga in cooperation with CHIP.